← Back to Screener
Terns Pharmaceuticals, Inc. Common Stock (TERN)
Price$52.74
Favorite Metrics
Price vs S&P 500 (26W)536.28%
Price vs S&P 500 (4W)-1.83%
Market Capitalization$6.09B
All Metrics
Book Value / Share (Quarterly)$8.96
P/TBV (Annual)0.87x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.73
Price vs S&P 500 (YTD)26.61%
EPS (TTM)$-1.03
10-Day Avg Trading Volume9.03M
EPS Excl Extra (TTM)$-1.03
EPS (Annual)$-1.12
ROI (Annual)-25.69%
Cash / Share (Quarterly)$9.07
ROA (Last FY)-24.41%
Revenue Growth TTM (YoY)-100.00%
EBITD / Share (TTM)$-1.18
ROE (5Y Avg)-34.50%
Cash Flow / Share (Annual)$-0.73
P/B Ratio6.05x
P/B Ratio (Quarterly)4.27x
Net Income / Employee (Annual)$-2
ROA (TTM)-19.37%
EPS Incl Extra (Annual)$-1.12
Current Ratio (Annual)62.41x
Quick Ratio (Quarterly)62.09x
3-Month Avg Trading Volume4.88M
52-Week Price Return2097.50%
Tangible BV / Share (Quarterly)$4.18
P/S Ratio (Annual)6086.90x
Asset Turnover (Annual)0.01x
52-Week High$53.19
EPS Excl Extra (Annual)$-1.12
CapEx CAGR (5Y)-45.82%
26-Week Price Return543.17%
Quick Ratio (Annual)62.09x
13-Week Price Return42.62%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)62.41x
Enterprise Value$5,562.155
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-4965.00%
Cash / Share (Annual)$9.07
3-Month Return Std Dev38.92%
Net Income / Employee (TTM)$-2
ROE (Last FY)-25.69%
EPS Basic Excl Extra (Annual)$-1.12
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.03
ROI (TTM)-20.02%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$5.16
Price vs S&P 500 (52W)2062.87%
Year-to-Date Return30.54%
5-Day Price Return0.11%
EPS Normalized (Annual)$-1.12
ROA (5Y Avg)-30.45%
Net Profit Margin (Annual)-5016.00%
Month-to-Date Return0.04%
Cash Flow / Share (TTM)$-1.27
EBITD / Share (Annual)$-1.28
Operating Margin (Annual)-4986.00%
ROI (5Y Avg)-32.65%
EPS Basic Excl Extra (TTM)$-1.03
P/TBV (Quarterly)0.94x
P/B Ratio (Annual)4.27x
Book Value / Share (Annual)$8.96
Price vs S&P 500 (13W)40.24%
Beta-0.41x
ROE (TTM)-20.02%
52-Week Low$2.23
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.24
4.24
4.28
3.82
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
TERNTerns Pharmaceuticals, Inc. Common Stock | — | -100.00% | — | — | $52.74 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing small-molecule therapies for non-alcoholic steatohepatitis (NASH) and other chronic liver diseases. The company's pipeline includes multiple candidates, including TERN-701, TERN-601, TERN-501, and TERN-800, designed for both single-agent and combination therapy approaches to address significant unmet clinical needs in liver disease treatment.